

VERTEX PHARMA - Faltering Pipeline and Sales

<https://marketpublishers.com/r/V8CDB145E89EN.html>

Date: January 2013

Pages: 4

Price: US\$ 140.00 (Single User License)

ID: V8CDB145E89EN

Abstracts

Vertex Pharma (VRTX) 4Q12/FY12 earnings and FY13 guidance (total revenue: \$1.1b to \$1.25b, ~20% de-growth over FY12) was not a surprise and VRTX is banking on success of its Cystic Fibrosis (CF) drugs in the pipeline for resurrection. VRTX endeavors could be too late in competing from “IFN free oral options” pipeline and uncertainty around combination drugs’ KALYDECO/VX-809 (CFTR Potentiator, PhII) ability to tap the larger CF market (del 508 mutation) could keep the stock volatile in 2013. VX-509 (PhIIb, RA, JAK 3 inhibitor) could attract partnership only if it shows..... For more detail, please read our report released on 31st January, 2013 on Vertex titled “Faltering Pipeline and Sales”

I would like to order

Product name: VERTEX PHARMA - Faltering Pipeline and Sales

Product link: <https://marketpublishers.com/r/V8CDB145E89EN.html>

Price: US\$ 140.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/V8CDB145E89EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970